Zalcitabine

Excreted Unchanged %
75
Half-Life (Normalesrd) Hours
1-2/>8
Plasma Protein Binding %
<4
Volume Of Distribution L/Kg
0.54
Dose For Normal Renal Function
0.75 mg q8h
Adjustment For Renal Failure Method
I, D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q12h[D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
q24h[D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data: Dose after dialysis
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 0.75 mg q12h, [D]
References
Gustavson LE, Fukuda EK, Rubio FA, Dunton AW. A pilot study of the bioavailability and pharmacokinetics of 2&#146; ,3&#146; -dideoxycytidine in patients with AIDS or AIDS-related complex. J Acquir Immune Defic Syndr. 1990; 3: 28-31. [PMID: 2152803] / Klecker RW Jr, Collins JM, Yarchoan RC, Thomas R, McAtee N, Broder S, et al. Pharmacokinetics of 2&#146; ,3&#146; -dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol. 1988; 28: 837-42. [PMID: 2852679]